Lewicki John A. 4

What Happened
John A. Lewicki, Chief Scientific Officer of Mereo BioPharma Group plc (MREO), was granted three derivative equity awards on February 1, 2026 totaling 331,550 shares (139,913 + 46,637 + 145,000). Each award shows an acquisition price of $0.00 (i.e., granted as compensation/derivative awards rather than an open‑market purchase). These are grants (transaction code A) and not sales.

Key Details

• Transaction date: February 1, 2026; Form 4 filed Feb 2, 2026 (appears timely).
• Grants listed: 139,913; 46,637; and 145,000 shares; aggregate 331,550 shares; reported price $0.00.
• Type: Derivative awards/grants (not a purchase or sale).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnotes: one award has a 25% vest on Feb 1, 2027 with remaining vesting monthly over the next three years; another vests in substantially equal monthly installments over one year from Feb 1, 2026; also notes that 1 ADS = 5 ordinary shares (check the filing to see whether amounts reported are ADS or ordinary shares).

Context
These grants are normal forms of executive compensation and are subject to vesting schedules (not immediately tradable shares). For retail investors: awards indicate company compensation decisions but are not the same signal as an insider buying stock with personal funds. Check the full Form 4 for details on whether the reported amounts are ADS or ordinary shares and for any additional conditions (exercise rights, tax withholding, or sale restrictions).